Warning: session_start(): open(/var/lib/php/session/sess_qu2lpmun8vkl8reb14k81cke73, O_RDWR) failed: Permission denied (13) in /var/www/html/realclearpolitics.com/httpdocs/congressional_bill_tracker/app/application/mvc.php on line 3 Warning: file_get_contents(http://congress.api.sunlightfoundation.com/bills?apikey=f323a285321542e3925601990ef5c589&congress=114&bill_type=hr&number=2416&fields=versions,latest_version): failed to open stream: HTTP request failed! HTTP/1.1 504 Gateway Time-out in /var/www/html/realclearpolitics.com/httpdocs/congressional_bill_tracker/app/application/model.php on line 738 RCP Congressional Bill Tracker - H.R. 2416

CONGRESSIONAL BILL TRACKER

Track Members of Congress & Get Email Updates on Their Activity

H.R. 2416: To amend the Federal Food, Drug, and Cosmetic Act to evaluate the potential use of evidence from clinical experience to help support the approval of new indications for approved drugs, and for other purposes.

Title: To amend the Federal Food, Drug, and Cosmetic Act to evaluate the potential use of evidence from clinical experience to help support the approval of new indications for approved drugs, and for other purposes.

Introduced: May 19, 2015 (114th Congress)

Sponsor: (No First Name Found) (No Last Name Found) [-]

Status: Referred to Committee - Referred to the Subcommittee on Health.

Summary: This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to establish a program to evaluate the potential use of evidence from clinical experience to support the approval of a new indication for an approved drug and to support post-approval study requirements. "Evidence from clinical experience" means data from sources other than randomized clinical trials, including from observational studies, registries, and therapeutic use. Before implementing the program, the FDA must establish a draft framework for the program that describes current sources of data from clinical experience, gaps in current data collection activities, standards and methodologies for collection and analysis of data from clinical experience, and priority areas, remaining challenges, and potential pilot opportunities that the program will address. The FDA must use the program to inform guidance to industry on the collection and use of evidence from clinical experience.

Votes

Warning: Unknown: open(/var/lib/php/session/sess_qu2lpmun8vkl8reb14k81cke73, O_RDWR) failed: Permission denied (13) in Unknown on line 0 Warning: Unknown: Failed to write session data (files). Please verify that the current setting of session.save_path is correct (/var/lib/php/session) in Unknown on line 0